Company Introduction

Newfoundland and Labrador Research Technologies (NLRT) is a Newfoundland and Labrador company incorporated in February 2010 by Dr. Majed Khraishi. NLRT was formed to commercialize discoveries made through clinical observation and research at its sister company, Nexus Clinical Research.

This self-directed research led to proprietary methods and tools for early detection of disease and an opportunity to provide leading edge biotechnology and scientific services to the world. Specifically, this self-directed, multidisciplinary approach to research (both Dermatology and Rheumatology specialties) led to the development of screening tools for a serious diseases that often goes undiagnosed, at least until the disease has progressed significantly. These diseases are rheumatologic conditions called Psoriatic Arthritis and Rheumatoid Arthritis.

This algorithmic process employed by NLRT screening tools is patent pending. This process can be used to develop tools for early detection of many other diseases in addition to PsA and RA. Others in development include screening tools for Ankylosing Spondylitis, cardiac conditions and diabetes as well as other inflammatory diseases.

Careers

We are hiring! We are looking for a candidate with a strong background in PHP coding and design, and in database design, implementation and management. Interested candidates should email their resume with a cover letter to: careers@nlrt.ca

News Release

Biologics May Cut Heart Risk in RA

Biologic therapy appears to lower the risk of cardiovascular disease (CVD) significantly among rheumatoid arthritis (RA) patients over two years – and also may reduce overall disease activity, say researchers from Newfoundland. A prospective study of more than 200 patients showed that biologics lowered their CVD risk by almost 12% over 24 months, the researchers reported at the recent annual meeting of the American College of Rheumatology in San Diego. more...

Release at Buenos-Aires, Argentina 2013

Systemic Lupus Erythematosus: Clinical Aspects

Release at ACR, San Diego, US 2013

EFFECT OF BIOLOGIC DISEASE MODIFIERS ON CARDIOVASCULAR RISK OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) – 2 YEARS PROSPECTIVE COHORT STUDY

Multicenter Validation of the Lupus Activity Scoring Tool (LAST) as Compared to the SELENA SLEDAI (SS) Modification

New medical diagnostic App empowers patients

The Psoriatic Arthritis Screening Questionnaire (PASQ) App Now Available

Please check out our new applications released on Apple App Store

The Psoriatic Arthritis Screening Questionnaire (PASQ) App iPhone version Now Available

The Psoriatic Arthritis Screening Questionnaire (PASQ) App iPad English version Now Available

The Psoriatic Arthritis Screening Questionnaire (PASQ) App iPad French version Now Available

The HAQ and DAS App iPad English version Now Available

The RADAI App iPhone English version Now Available

The CVD App iPad English version Now Available

Please check out our new applications released on MarketPlace using on Windows Phone

The Psoriatic Arthritis Screening Questionnaire (PASQ) Windows Phone version Now Available

The RADAI Windows Phone version Now Available

Careers Privacy Policy Contact Us Site Map